Baris, ElifArici, M. Aylin2023-06-162023-06-1620212458-89382564-7288https://doi.org/10.30621/jbachs.869857https://search.trdizin.gov.tr/yayin/detay/436595https://hdl.handle.net/20.500.14365/2454Severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) or coronavirus infectious disease (COVID-19) outbreak is continued to spread all over the world recently with the high mortality and morbidity rates. It is also known well COVID-19 is leading causes of acute lung injury and acute respiratory distress syndrome (ARDS), sepsis and multiorgan failure. Current treatment of COVID-19, includes different strategies targeting preventing viral replication or treating secondary infections and decreasing exaggerated immune response. Although antiviral, antimicrobial, immunomodulatory agents including anti-cytokines and glucocorticoids have been currently applied, there is lack of a specific treatment for COVID-19. In this review, possible therapeutic roles of cholinomimetic drugs in the control of COVID-19 related inflammation is discussed.eninfo:eu-repo/semantics/openAccessCholinomimetic drugsCOVID-19SARS-CoV-2Cytokine StormVagus NerveNicotineEndotoxinArticle10.30621/jbachs.869857